- Biomarkers show the potential of NeuroSense's combination
drug CogniC to treat Alzheimer's disease
- CogniC is expected to advance into clinical trials in
CAMBRIDGE, Mass., June 30,
2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
(NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for
severe neurodegenerative diseases, today announced results from a
biomarker study conducted to evaluate the potential of CogniC,
NeuroSense's combination drug for the treatment of Alzheimer's
NeuroSense's biomarker study identified several biomarkers
associated with AD, which indicate CogniC's mechanism of action may
be effective in targeting the pathways involved in the disease,
such as miRNA dysregulation, lysosomal dysfunction, and impaired
autophagy. Additionally, hallmarks of AD were detected, such as
increased levels of amyloid-β (Aβ) and intracellular aggregates of
tau protein among the panel of biomarkers evaluated.
Preliminary results revealed high levels of TDP-43 in people who
suffer from AD, when compared to the healthy control
group. These findings provide additional support for TDP-43
pathology as an integral part of AD, reinforcing the growing body
of evidence in AD research regarding the role of TDP-43 in
neurodegenerative pathologies. TDP-43 has been found in up to
57% of AD cases and aggregates of TDP-43 have been shown to be
cytotoxic both in vitro and in
vivo.  NeuroSense's platform
combination therapy technology, the basis of CogniC, has already
shown to impact TDP-43 in a Phase IIa clinical trial biomarker
study in another neurodegenerative disease, amyotrophic lateral
"Having identified these promising biomarkers, which have the
potential to be modulated by CogniC, we are now preparing to carry
out a clinical proof-of-concept study in conjunction with a leading
AD clinic. The study is expected to commence in 2023," stated
NeuroSense CEO, Alon Ben-Noon.
NeuroSense is conducting its AD biomarker study via utilization
of Neuron-Derived Exosomes (NDE), a cutting-edge technology which
allows one to observe key alterations in biomarkers found in the
central nervous system in a non-invasive manner via collection of
blood samples. Following further analysis, NeuroSense expects to
share more detailed results on additional novel biomarkers that
were evaluated in this study through scientific conferences and
Transactive response DNA binding protein of 43 kDa (TDP-43) is
involved in regulation of gene expression. AD patients with TDP-43
pathology have increased severity of cognitive impairment compared
to those without TDP-43 pathology. Additionally, the strongest
genetic risk factor for AD, apolipoprotein E4 (APOE4), is
associated with increased frequency of TDP-43
About Alzheimer's Disease
Alzheimer's disease (AD) is a brain disorder that slowly
destroys memory and thinking skills. AD is the most common cause of
dementia, a general term for memory loss and other cognitive
abilities serious enough to interfere with daily life. Alzheimer's
disease accounts for 60-80% of dementia cases. The global AD
treatment market is expected to grow to $5
billion in 2022.
CogniC is a combination drug for the treatment of Alzheimer's
disease and is based on NeuroSense's combination platform
technology. The lead drug candidate in that platform is PrimeC,
which is currently being evaluated in a Phase IIb study for the
treatment of amyotrophic lateral sclerosis (ALS).
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's
disease, among others, represent one of the most significant unmet
medical needs of our time, with limited effective therapeutic
options available for patients to date. Due to the complexity of
neurodegenerative diseases and based on strong scientific research
on a large panel of related biomarkers, NeuroSense's strategy is to
develop combined therapies targeting multiple pathways associated
with these diseases.
For additional information, we invite you to visit
our website and follow us
on LinkedIn and Twitter.
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on NeuroSense
Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and include statements regarding the company's CogniC development
program; the potential for CogniC to safely and effectively target
AD; preclinical and clinical data for CogniC; the timing of current
and future clinical trials; the nature, strategy and focus of the
company and further updates with respect thereto; and the
development and commercial potential of any product candidates of
the company. Further, certain forward-looking statements are based
on assumptions as to future events that may not prove to be
accurate. Forward-looking statements contained in this announcement
are made as of this date, and NeuroSense Therapeutics Ltd.
undertakes no duty to update such information except as required
under applicable law.
 Meneses, A., Koga, S., O'Leary, J. et
al. TDP-43 Pathology in Alzheimer's Disease. Mol
Neurodegeneration 16, 84 (2021).
View original content to download